Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia
Sponsor: Lantu Biopharma
Summary
This is an interventional study to evaluate the safety and efficacy of autologous Hematopoietic Stem and Progenitor Cells (HSPCs) transduced with lentiviral vector encoding functional hemoglobin subunit beta (HBB) gene in patients with transfusion-dependent beta-thalassemia.
Official title: An Open-label Clinical Trial of Ex Vivo Beta-globin Lentiviral Vector Transduction of Autologous CD34+HSPCs (Vebeglogene Autotemcel) for the Treatment of Transfusion Dependent Beta-thalassemia Patients
Key Details
Gender
All
Age Range
Any - 35 Years
Study Type
INTERVENTIONAL
Enrollment
6
Start Date
2024-05-11
Completion Date
2027-08-01
Last Updated
2025-11-25
Healthy Volunteers
No
Conditions
Interventions
Vebeglogene autotemcel
Autologous HSPCs transduced with self-inactivating lentiviral vector encoding functional HBB gene and resuspended in cryopreservative solution in the final immediate container for the intended medical use.
Locations (2)
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Kunming, Yunnan, China
Kunming Hope of Health Hospital
Kunming, Yunnan, China